FDA-Approved Renal Denervation Lowers Blood Pressure

Close-up of a patients hand during a medical examination with monitoring equipment

Renal denervation has moved from experimental idea to FDA-approved option for a narrow group of patients whose blood pressure remains dangerous despite multiple medications, but its promise—illustrated by cases like a Michigan woman who had three strokes—has to be understood alongside its risks and evidence on long‑term outcomes.^[1]

Key Points

Renal denervation is a minimally invasive catheter procedure that disrupts overactive kidney nerves to achieve a modest but meaningful reduction in blood pressure, typically similar to adding one more medication.^[10]
It is approved and positioned as an adjunct for resistant or uncontrolled hypertension after lifestyle changes and several drugs have failed, not as a first‑line or stand‑alone cure.^[5]
Randomized sham‑controlled trials and large registries show a consistent blood‑pressure–lowering effect and a low rate of serious complications, but the procedure is not effective for everyone and benefits vary.^[10]
There is still no high‑quality evidence that renal denervation itself reduces strokes, heart attacks, or mortality; current use is justified by blood pressure reduction as a surrogate, not by hard outcome data.
Human‑interest stories, such as a Michigan patient whose pressure normalized and medications dropped after the procedure, are real but inherently anecdotal and cannot be generalized to all patients.^[1]^[3]

How renal denervation lowers blood pressure

Blood pressure is regulated in part by the sympathetic nerves that run between the kidneys and the brain. Those nerves influence salt and water balance, blood vessel tone, and hormone release; in many people with hypertension, the system is chronically overactive. Renal denervation targets this circuitry directly. Using a catheter threaded through an artery—typically in the groin—interventionalists deliver radiofrequency or ultrasound energy to the walls of the renal arteries, heating them just enough to damage the surrounding sympathetic nerve fibers while preserving the vessel itself.^[1]^[10] Interrupting these signals reduces the kidneys’ contribution to elevated blood pressure, regardless of the original cause of hypertension.^[1]

In practical terms, the procedure usually takes 45–60 minutes under mild sedation.^[1]^[5]^[7] A guidewire and specialized catheter are advanced into each renal artery. The operator performs a series of ablations in a spiral or segmental pattern along the main vessel and branches, aiming to cover all regions where nerves cluster.^[1]^[10] Patients typically go home the same day or after an overnight stay.^[10] Blood pressure does not normalize instantly; instead, there is often a modest immediate drop followed by a gradual decline over weeks to months as nerve activity diminishes further. This time course is exactly what the Michigan woman described: her blood pressure stabilized in the normal range over about three and a half months after the procedure.^[1]^[3]

From trial concept to FDA‑approved therapy

Renal denervation is not new as a concept. Early catheter systems were tested more than a decade ago, but initial enthusiasm cooled after a large trial failed to show significant benefit over a sham procedure. That failure forced a redesign: more precise devices, better patient selection, rigorous sham controls, and ambulatory blood pressure endpoints. The newer wave of trials—such as the RADIANCE program and SPYRAL studies—produced a consistent signal. In RADIANCE II, for example, daytime ambulatory systolic pressure fell about 8 mmHg in the treated group versus about 2 mmHg in the sham group at two months, for a baseline‑adjusted difference of roughly 6 mmHg.^[10] Pooled analyses of several ultrasound‑based trials reported similarly modest but statistically robust reductions and a favorable safety profile at short‑term follow‑up.^[10]

On the strength of this body of evidence, the U.S. Food and Drug Administration in 2023 approved renal denervation as an adjunctive treatment for patients whose blood pressure remains uncontrolled despite lifestyle changes and antihypertensive medications. Major health systems and academic centers now describe it as an option for “resistant hypertension,” typically defined as blood pressure that remains above goal on three or more drugs of different classes, ideally including a diuretic, or controlled only with four or more agents.^[5] Institutions from Cleveland Clinic to UNC and UCSF present it as a tool to supplement—not replace—standard therapy for carefully selected patients.^[4]

How much benefit can patients realistically expect?

The core effect size matters because it anchors expectations. Multiple expert centers and scientific reviews converge on the same range: renal denervation lowers systolic blood pressure by roughly 5–10 mmHg on average, comparable to adding one well‑chosen antihypertensive medication.^[7] Cleveland Clinic explicitly notes that the procedure “may work as well as taking one blood pressure medicine,” and that typical reductions fall within that 5–10 mmHg band. The European Society of Cardiology’s review of pros and cons reaches a similar conclusion, translating the observed effect on ambulatory blood pressure into the equivalent of one additional drug. For an individual whose systolic pressure runs 170 mmHg despite treatment, bringing that down into the low 160s may not sound dramatic, but it represents a meaningful reduction in long‑term cardiovascular risk.

That average, however, hides substantial variability. Some patients experience striking drops and are able to reduce their medication burden; others see little to no change. UNC estimates that about 60–70% of patients see a “meaningful” decrease after the procedure. The Michigan case falls toward the favorable end of that spectrum. After years of dangerous readings and three strokes despite ten medications, she underwent renal denervation; over the next several months, her blood pressure remained in the normal range and her regimen shrank to four drugs, accompanied by better energy and quality of life.^[1]^[3] That story is medically plausible given the range of responses described in trials and practice, but it is also exactly the kind of outlier outcome that makes for compelling television. The evidence base reminds us that not every patient will see such a transformation.

Safety profile, complications, and what “minimally invasive” really means

Calling a procedure “minimally invasive” risks lulling people into thinking it is trivial. Renal denervation requires arterial access, contrast dye, and fluoroscopy; all carry hazards. Regulatory reviews and contemporary trials nonetheless paint a reassuring safety picture. Meta‑analyses of randomized studies between 2013 and 2022 found no significant difference in major adverse events between denervation and control groups, with serious complications like access‑site bleeding, renal artery dissection, or death occurring in less than 1% of patients. Longer‑term registry data, such as the Global SYMPLICITY Registry encompassing thousands of patients, have not revealed progressive kidney damage beyond what would be expected from severe hypertension itself.^[10]

Certain complications do occur. A review of more than 5,700 patients found renal artery stenosis or dissection requiring stenting in about 0.2% per year, a rate similar to the background incidence in hypertensive populations. Procedure‑related events documented in pooled trials include a pseudoaneurysm at the access site and vasovagal response, both managed successfully.^[10] Institutions that perform renal denervation emphasize groin bleeding and transient post‑procedural pain as the most common issues; serious injury to the kidneys or renal arteries is described as rare but not impossible. Device manufacturers themselves list worst‑case risks that include kidney damage, arterial perforation, and need for dialysis, underscoring that even a low‑risk vascular procedure warrants respect.

What the Michigan story illustrates—and what it does not

Local coverage of the Corewell Health case captures exactly why renal denervation generates interest. Jamie Pepperman, in her forties, lived for nearly a decade with blood pressure high enough to cause three strokes despite a double‑digit medication list.^[1]^[3] That pattern fits the definition of treatment‑resistant hypertension, though the public story does not provide details like ambulatory monitoring, adherence checks, or work‑up for secondary causes. After undergoing renal denervation, she reports three and a half months of consistently normal readings, with her medication list cut from ten drugs to four and a marked improvement in energy and mood.^[1]^[3] Her interventional cardiologist describes being pleasantly surprised by how well she responded.^[1]

Nothing in the broader evidence renders this narrative implausible. Trials and registries confirm that some patients experience substantial, durable reductions in blood pressure, with follow‑up studies documenting sustained benefit for up to seven years in selected cohorts.^[1]^[10] Hospitals across Michigan and the broader United States, including Trinity Health Grand Rapids and others, now routinely offer the procedure to eligible patients and report good early outcomes.^[5]^[7] What the story cannot do, by its nature, is prove that renal denervation will prevent Pepperman—or anyone else—from ever having another stroke, or that her experience is representative of most patients.

What this means going forward

Renal denervation has crossed a significant threshold: it is no longer an experimental curiosity but an FDA‑approved, real‑world tool deployed in health systems across Michigan and the country for carefully selected patients who have run out of conventional options.^[1]^[5]^[6]^[7] The Michigan woman’s experience is an early example of what the procedure can deliver at its best: clinically meaningful blood pressure control, fewer medications, and a renewed sense of safety after years of living in the shadow of stroke.

For patients and clinicians, the task now is to integrate this new option without either overselling or underusing it. The evidence supports a clear, measured stance: renal denervation provides a modest, additive reduction in blood pressure with a low incidence of serious complications, and it appears durable over several years in many patients.^[10] It is not a cure, not a replacement for medication or lifestyle change, and not yet a proven shield against future cardiovascular events. Used within those boundaries, it offers something genuinely valuable to a small but high‑risk population: another lever to pull when the usual tools have been exhausted and the stakes, as Jamie Pepperman’s story underscores, could not be higher.